The estimated Net Worth of Reed L Benson is at least $489 Tisíc dollars as of 19 May 2021. Mr. Benson owns over 108,334 units of Co-Diagnostics Inc stock worth over $136,501 and over the last 7 years he sold CODX stock worth over $0. In addition, he makes $352,500 as Chief Financial Officer a Secretary at Co-Diagnostics Inc.
Reed has made over 2 trades of the Co-Diagnostics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 108,334 units of CODX stock worth $284,918 on 19 May 2021.
The largest trade he's ever made was exercising 108,334 units of Co-Diagnostics Inc stock on 19 May 2021 worth over $284,918. On average, Reed trades about 29,762 units every 25 days since 2017. As of 19 May 2021 he still owns at least 108,334 units of Co-Diagnostics Inc stock.
You can see the complete history of Mr. Benson stock trades at the bottom of the page.
Reed L Benson serves as Chief Financial Officer, Secretary of the Company. He has been Chief Financial Officer and Secretary from November 2014 to the present and a director from November 2014 to May 2017. Since September, 2008 to the present, in addition to the private practice of law, he is a founder and partner of Legends Capital Group, LLC, a privately held venture capital group that identifies investment opportunities in natural resources, bio tech and technology fields. From October 2004 to September 2008 he was employed as Chief Financial Officer, Secretary, and General Counsel and member of Board of Directors of Broadcast International, Inc., a publicly traded communications services company. From 2001 to October 2004, he was in the private practice of law where his practice focused on tax and business related matters. From July 1995 to January 2001 he was secretary and general counsel for Data Broadcasting Corporation, a provider of market information to individual investors. Mr. Benson received his J.D. degree from the University of Utah School of Law in 1976 and a Bachelor of Science Degree in Accounting from the University of Utah in 1971. Mr. Benson became a Certified Public Accountant in 1974. Mr. Benson’s experience in finance, accounting and business consulting, together with his role as our CFO and prior public company directorship, provide Mr. Benson with expertise enabling critical input to our company.
As the Chief Financial Officer a Secretary of Co-Diagnostics Inc, the total compensation of Reed Benson at Co-Diagnostics Inc is $352,500. There are 2 executives at Co-Diagnostics Inc getting paid more, with Dwight H. Egan having the highest compensation of $676,875.
Reed Benson is 73, he's been the Chief Financial Officer a Secretary of Co-Diagnostics Inc since 2017. There are 1 older and 8 younger executives at Co-Diagnostics Inc. The oldest executive at Co-Diagnostics Inc is Richard Serbin, 75, who is the Independent Director.
Reed's mailing address filed with the SEC is 2401 S. FOOTHILL DRIVE SUITE D, , SALT LAKE CITY, UT, 84109.
Over the last 7 years, insiders at Co-Diagnostics Inc have traded over $2,459,090 worth of Co-Diagnostics Inc stock and bought 8,205 units worth $11,819,010 . The most active insiders traders include Reed L Benson, James B Nelson a Dwight H Egan. On average, Co-Diagnostics Inc executives and independent directors trade stock every 79 days with the average trade being worth of $38,652. The most recent stock trade was executed by Brian Lee Brown on 20 March 2023, trading 3,000 units of CODX stock currently worth $5,700.
co-diagnostics, inc. is a molecular diagnostics company that has acquired certain unique, patented diagnostic testing technology. a utah corporation headquartered in sandy, utah, its primary business is to commercialize its unique, patented technology through sales, development and licensing. the technology is embodied in three patent applications and certain trade secrets, which make dna testing for diseases faster, higher in performance, and more cost efficient than traditional technologies of the past. the company has undertaken completely innovative approaches to develop novel molecular technologies using biophysical models and statistical bioinformatics. it has successfully developed and commercialized a series of assays in the infectious disease area to demonstrate the capability of its technology. the technology on which the inventions are based were created by reference to certain mathematical models invented, designed and refined by dr. brent c. satterfield. the inventions are
Co-Diagnostics Inc executives and other stock owners filed with the SEC include: